DCM
ATXS

Driehaus Capital Management’s Astria Therapeutics ATXS Stock Holding History

Driehaus Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,433,769
Closed -$10.4M – 409
2025
Q3 		$10.4M Buy
1,433,769
+14,436
+1% +$97.7K 0.07% 274
2025
Q2 		$7.61M Sell
1,419,333
-8,884
-0.6% -$43.1K 0.06% 280
2025
Q1 		$7.63M Sell
1,428,217
-133,574
-9% -$934K 0.07% 273
2024
Q4 		$14M Sell
1,561,791
-55,837
-3% -$593K 0.12% 210
2024
Q3 		$17.8M Sell
1,617,628
-132,294
-8% -$1.47M 0.15% 185
2024
Q2 		$15.9M Sell
1,749,922
-15,057
-0.9% -$147K 0.15% 176
2024
Q1 		$24.8M Buy
1,764,979
+1,339,615
+315% +$16.7M 0.25% 120
2023
Q4 		$3.27M Sell
425,364
-1,028,840
-71% -$5.69M 0.04% 280
2023
Q3 		$10.8M Sell
1,454,204
-1,444
-0.1% -$12.3K 0.14% 196
2023
Q2 		$12.1M Buy
1,455,648
+22,974
+2% +$265K 0.15% 194
2023
Q1 		$19.1M Buy
1,432,674
+95,359
+7% +$1.29M 0.27% 124
2022
Q4 		$19.9M Buy
1,337,315
+680,954
+104% +$7.02M 0.3% 113
2022
Q3 		$5.93M Buy
+656,361
New +$4.4M 0.09% 250

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Driehaus Capital Management's ATXS Position: Q4 2025 in Review

Driehaus Capital Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 1,433,769 shares — an estimated $10.4M sold.

Driehaus Capital Management first reported a position in ATXS in Q3 2022 and held it in 13 quarters. The position peaked at $24.8M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Driehaus Capital Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 1,433,769 Astria Therapeutics shares in Q4 2025, an estimated $10.4M.
  • Driehaus Capital Management first reported a position in Astria Therapeutics in Q3 2022 and held it in 13 quarters.
  • Driehaus Capital Management's Astria Therapeutics position peaked at $24.8M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.